These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7673253)

  • 1. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
    Wallasch C; Weiss FU; Niederfellner G; Jallal B; Issing W; Ullrich A
    EMBO J; 1995 Sep; 14(17):4267-75. PubMed ID: 7556068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NDF/heregulin stimulates the phosphorylation of Her3/erbB3.
    Kita YA; Barff J; Luo Y; Wen D; Brankow D; Hu S; Liu N; Prigent SA; Gullick WJ; Nicolson M
    FEBS Lett; 1994 Jul; 349(1):139-43. PubMed ID: 8045292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3.
    Vartanian T; Goodearl A; Viehöver A; Fischbach G
    J Cell Biol; 1997 Apr; 137(1):211-20. PubMed ID: 9105049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family.
    Schelfhout VR; Coene ED; Delaey B; Thys S; Page DL; De Potter CR
    J Natl Cancer Inst; 2000 Apr; 92(8):622-8. PubMed ID: 10772679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
    Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
    J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.
    Plowman GD; Green JM; Culouscou JM; Carlton GW; Rothwell VM; Buckley S
    Nature; 1993 Dec; 366(6454):473-5. PubMed ID: 7902537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.
    Chen X; Levkowitz G; Tzahar E; Karunagaran D; Lavi S; Ben-Baruch N; Leitner O; Ratzkin BJ; Bacus SS; Yarden Y
    J Biol Chem; 1996 Mar; 271(13):7620-9. PubMed ID: 8631797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.
    Culouscou JM; Plowman GD; Carlton GW; Green JM; Shoyab M
    J Biol Chem; 1993 Sep; 268(25):18407-10. PubMed ID: 7689552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
    Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
    Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.
    Siegall CB; Bacus SS; Cohen BD; Plowman GD; Mixan B; Chace D; Chin DM; Goetze A; Green JM; Hellström I
    J Biol Chem; 1995 Mar; 270(13):7625-30. PubMed ID: 7535774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.
    Gilbertson RJ; Perry RH; Kelly PJ; Pearson AD; Lunec J
    Cancer Res; 1997 Aug; 57(15):3272-80. PubMed ID: 9242460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heregulins and the ErbB-2/3/4 receptors in gliomas.
    Westphal M; Meima L; Szonyi E; Lofgren J; Meissner H; Hamel W; Nikolics K; Sliwkowski MX
    J Neurooncol; 1997 Dec; 35(3):335-46. PubMed ID: 9440030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.
    Horan T; Wen J; Arakawa T; Liu N; Brankow D; Hu S; Ratzkin B; Philo JS
    J Biol Chem; 1995 Oct; 270(41):24604-8. PubMed ID: 7592681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).
    Sollome JJ; Thavathiru E; Camenisch TD; Vaillancourt RR
    Cell Signal; 2014 Jan; 26(1):70-82. PubMed ID: 24036211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
    Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
    Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.